Cytokinetics (CYTK) announced that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy in Greater China. Aficamten is a cardiac myosin inhibitor for the potential treatment of patients with HCM. In 2020, Corxel acquired the rights to develop and commercialize aficamten in Greater China from Cytokinetics in accordance with Cytokinetics’ global registration programs. Aficamten received Breakthrough Therapy Designation for the treatment of symptomatic obstructive hypertrophic cardiomyopathy from The Center for Drug Evaluation of the China National Medical Products Administration which recently accepted the New Drug Application for aficamten tablets for the treatment of oHCM for Priority Review. Sanofi will now acquire Corxel’s rights relating to aficamten in Greater China for an undisclosed amount. Cytokinetics remains eligible to receive up to $150M in development and commercial milestone payments from Sanofi as well as royalties in the low-to-high teens on future sales of aficamten in Greater China. Cytokinetics is now also eligible to receive additional undisclosed payments in connection with the execution of the agreement between Sanofi and Corxel.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CYTK:
- Cytokinetics price target raised to $82 from $80 at RBC Capital
- Cytokinetics opens enrollment for COMET-HF Phase 3 trial
- Cytokinetics announces FDA acceptance of NDA for aficamten
- Cytokinetics price target raised to $103 from $99 at Mizuho
- Bayer Secures Deal for Cytokinetics’ Heart Drug in Japan
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
